Literature DB >> 19450680

Role of the IRF-1 enhancer domain in signalling polyubiquitination and degradation.

Emmanuelle Pion1, Vikram Narayan, Mirjam Eckert, Kathryn L Ball.   

Abstract

The interferon regulated transcription factor IRF-1 is a tumour suppressor protein that is activated in response to viral infection and cell signalling activated by double stranded DNA lesions. IRF-1 has a short half-life (t(0.5) 20-40 min) allowing rapid changes in steady state levels by modulating its rate of degradation and/or synthesis. However, little is known about the pathway(s) leading to IRF-1 protein degradation or what determines the rate of degradation in cells. Here we establish a role for discrete motifs in the enhancer domain of IRF-1 in directing polyubiquitination and degradation. By studying the structure of the enhancer domain as related to its role in the turnover of IRF-1 we have demonstrated that this region is not subject to modification by ubiquitin but rather that it contains both an ubiquitination signal and a distinct degradation signal. Removal of the C-terminal 70 amino acids from IRF-1 inhibits both its degradation and polyubiquitination, whereas removal of the C-terminal 25 amino acids inhibits degradation of the protein but does not prevent its ubiquitination. Furthermore, consistent with the C-terminus being involved in targeting or recognition by an E3-ligase or associated protein(s) the enhancer domain can act in trans to inhibit IRF-1 ubiquitination by endogenous E3-ligase activity. The identification of structural determinants that signals IRF-1 polyubiquitination and which can be uncoupled from IRF-1 degradation lends support to the idea that the degradation of selective substrates can be regulated at multiple steps in the ubiquitin-proteasome system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450680     DOI: 10.1016/j.cellsig.2009.05.004

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  13 in total

1.  Docking-dependent ubiquitination of the interferon regulatory factor-1 tumor suppressor protein by the ubiquitin ligase CHIP.

Authors:  Vikram Narayan; Emmanuelle Pion; Vivien Landré; Petr Müller; Kathryn L Ball
Journal:  J Biol Chem       Date:  2010-10-14       Impact factor: 5.157

Review 2.  The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases.

Authors:  Xiao-Jing Zhang; Ding-Sheng Jiang; Hongliang Li
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain.

Authors:  Angeli Möller; Emmanuelle Pion; Vikram Narayan; Kathryn L Ball
Journal:  J Biol Chem       Date:  2010-09-03       Impact factor: 5.157

4.  A multiprotein binding interface in an intrinsically disordered region of the tumor suppressor protein interferon regulatory factor-1.

Authors:  Vikram Narayan; Petr Halada; Lenka Hernychová; Yuh Ping Chong; Jitka Žáková; Ted R Hupp; Borivoj Vojtesek; Kathryn L Ball
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

5.  Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8.

Authors:  Robin Ireland; Rong Wang; Joshua B Alinger; Pamela Small; Catharine M Bosio
Journal:  J Immunol       Date:  2013-07-01       Impact factor: 5.422

6.  Cooperative regulation of the interferon regulatory factor-1 tumor suppressor protein by core components of the molecular chaperone machinery.

Authors:  Vikram Narayan; Mirjam Eckert; Alicja Zylicz; Maciej Zylicz; Kathryn L Ball
Journal:  J Biol Chem       Date:  2009-06-05       Impact factor: 5.157

7.  Regulation of transcriptional activators by DNA-binding domain ubiquitination.

Authors:  Vivien Landré; Bhindu Revi; Maria Gil Mir; Chandra Verma; Ted R Hupp; Nick Gilbert; Kathryn L Ball
Journal:  Cell Death Differ       Date:  2017-03-31       Impact factor: 15.828

8.  The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer.

Authors:  J L Schwartz; A N Shajahan; R Clarke
Journal:  Int J Breast Cancer       Date:  2011-07-03

9.  HIV-1 Tat Recruits HDM2 E3 Ligase To Target IRF-1 for Ubiquitination and Proteasomal Degradation.

Authors:  Anna Lisa Remoli; Giulia Marsili; Edvige Perrotti; Chiara Acchioni; Marco Sgarbanti; Alessandra Borsetti; John Hiscott; Angela Battistini
Journal:  mBio       Date:  2016-10-18       Impact factor: 7.867

10.  Protein-Protein Interactions Modulate the Docking-Dependent E3-Ubiquitin Ligase Activity of Carboxy-Terminus of Hsc70-Interacting Protein (CHIP).

Authors:  Vikram Narayan; Vivien Landré; Jia Ning; Lenka Hernychova; Petr Muller; Chandra Verma; Malcolm D Walkinshaw; Elizabeth A Blackburn; Kathryn L Ball
Journal:  Mol Cell Proteomics       Date:  2015-09-01       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.